PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that it has acquired chemagen Biopolymer-Technologie AG, a key player in the field of automated nucleic acid isolation, as part of the Company's strategy to advance its offerings to the molecular diagnostics and research markets.
Daniel R. Marshak, PhD, chief scientific officer and president, Emerging Diagnostics, PerkinElmer, said, "The addition of chemagen's complementary products to PerkinElmer's portfolio will provide the Company with robust platforms and solutions to meet the needs of the rapidly evolving molecular diagnostics market. The hardware and reagent capabilities brought by chemagen include a total solution in nucleic acid sample preparation, with automation-enabling features that can power high throughput applications in research, screening, and diagnostics."
He added, "Nucleic acids are the building blocks of DNA and RNA, modulators of genetic function and information. Our ability to provide automated nucleic acid isolation technologies through this acquisition significantly facilitates applications such as large-scale pathogen detection in blood banking, human genetics applications such as HLA typing, autoimmune analysis and tissue rejection analysis. PerkinElmer has worked with chemagen for years to provide automated liquid-handling platforms with DNA preparation capabilities. chemagen is a natural fit with our business."